$TLX

Telix Pharmaceuticals' Zircaix achieved 98% accuracy in detecting both clear and non-clear cell kidney cancers in Phase 3 trials, expanding its clinical potential and market opportunity.

Telix Pharmaceuticals' glioma imaging candidate TLX101-Px gains European regulatory validation, entering 210-day review phase with potential market approval expected.

Telix's next-gen prostate cancer therapy shows reduced organ toxicity in Phase 2 trial, expanding into earlier-stage disease applications with expanded clinical potential.

Telix Pharmaceuticals hosts webinar April 30 discussing next-gen PSMA cancer therapy pipeline, featuring OPTIMAL-PSMA2 trial data on TLX597-Tx candidate.

Telix Pharma secures $2.14B partnership with Regeneron for solid tumor radiopharmaceuticals while reporting 11% quarterly revenue growth and FDA acceptance of brain cancer imaging application.

FDA accepts Telix's Pixclara NDA for glioma imaging with September 2026 decision target. Orphan Drug designation provides competitive advantages.

Telix Pharmaceuticals appoints two Non-Executive Directors: former Pfizer CMO Maria Rivas and corporate finance leader William Jellison, effective May 2026.

Telix Pharma reports 11% Q1 revenue growth to US$230M, reaffirms FY guidance, while advancing prostate and brain cancer pipelines through Phase 3 and regulatory milestones.

Telix Pharmaceuticals appoints experienced life sciences executive David Gill as Non-Executive Director, with planned succession to Chair role, bringing 35+ years of CFO and commercial expertise.

Telix resubmits FDA application for Pixclara, a brain cancer imaging agent with Orphan Drug and Fast Track designations, addressing a regulatory Complete Response Letter.

Telix Pharmaceuticals' TLX591-Tx meets Phase 3 safety objectives in prostate cancer trial, advancing toward U.S. expansion with FDA.

Telix Pharmaceuticals announces March 2026 webinar on PSMA-PET/CT imaging innovations, featuring leading oncology experts discussing prostate cancer detection advances.

Telix Pharmaceuticals expands its nuclear medicine presence with approved cancer-targeting drugs and 56% revenue growth, positioning itself as a key player in oncology diagnostics and therapeutics.